Tenascin-C and CVD events in T2DM – a prospective cohort study

Any IBL product introduced in this IBL news is applicable for research use only and it cannot be used for diagnosis or medical purpose.

The association between the mortality risks of type 2 diabetes patients with cardiovascular diseases (CVD) and serum Tenascin-C level was assessed at both a primary endpoint and major adverse CV events (MACE)* as a secondary endpoint in the prospective cohort study (the SURDIAGENE**) reported in the following new articles (Barnabas Gellen et al, Diabetologia. 2020 May;63(5):915-923).

Serum tenascin-C is independently associated with increased major adverse cardiovascular events and death in individuals with type 2 diabetes: a French prospective cohort. Gellen B et al. Diabetologia. 2020;63(5):915-923.

*MACE: CV death, non-fatal myocardial infarction or stroke
**The SURDIAGENE: 1321 type 2 diabetes patients were followed during median 89 months.

In conclusion in this study, it has been suggested that elevating Tenascin-C levels in individuals with type 2 diabetes is relevantly associated with both increased risk of all-cause death and increased risk of MACE.

(Background)　
Tenascin-C is an extracellular matrix protein highly expressed in inflammatory tissues and known to be elevated in heart disease such as acute myocardial infarction or dilated cardiomyopathy.

So far it has not been reported its implications in type 2 diabetes, a condition known to associate with chronic low-grade inflammation and increased CV risk.

Meanwhile, recent study using big data approach identified among others Tenascin-C as an independent determinant of CV outcomes or death in individuals (>8400) with dysglycemia.

It is of interest that this report concluded that measuring Tenascin-C in addition to established prognostic biomarkers could distinguish risk layers in individuals with type 2 diabetes.

For measurement of serum Tenascin-C, https://www.ibl-america.com/tenascin-c-large-fn-ii... is used in this report.